Nanoparticles reprogram immune cells to fight cancerPhys.OrgThe study provides proof-of-principle that the nanoparticles can educate the immune system to target cancer cells. Stephan and his team designed the new CAR genes to integrate into chromosomes… Continue reading
EurekAlert (press release) |
Scientists work to strengthen the synergy of chemotherapy and immunotherapy against cancer
EurekAlert (press release) (April 17, 2017) – In the war on cancer, powerful chemotherapy agents are increasingly packaged with immunotherapy that primes a patient’s immune system to better battle the disease. To strengthen their synergy, scientists are now focusing on immune … |
The Hippocratic Post (blog) |
Gene Therapy Technologies, Markets and Companies Report 2017 …
GlobeNewswire (press release) Dublin, April 17, 2017 (GLOBE NEWSWIRE) — Research and Markets has announced the addition of Jain PharmaBiotech’s new report “Gene Therapy … Gene therapy for nervous system disorders – The Hippocratic PostThe Hippocratic Post (blog) |
The Hippocratic Post (blog) |
Gene Therapy Technologies, Markets and Companies Report 2017 …
Yahoo Finance Dublin, April 17, 2017– Research and Markets has announced the addition of Jain PharmaBiotech’s new report “Gene Therapy- Technologies, Markets and … Gene therapy for nervous system disorders – The Hippocratic PostThe Hippocratic Post (blog) |
Immuno-Oncology News |
Reolysin-Taxol Combo Increases Breast Cancer Patients’ Survival Rate
Immuno-Oncology News Oncolytics Biotech is partnering with other companies to develop immunotherapy and immunomodulatory applications for Reolysin, which improved breast cancer survival rates. A combination of Reolysin and the chemotherapy Taxol (paclitaxel) increased … |
Petro Global News 24 |
CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with …
Yahoo Finance CRISPR Therapeutics and Casebia will have an option to exclusively license AAV vectors with desired properties for use in their in vivo gene-editing programs. StrideBio will receive development funding, milestones and royalties on licensed vectors, and … Crispr Therapeutics AG (CRSP) Given Consensus Recommendation of “Strong Buy” by AnalystsThe Cerbat Gem The Brokerages Set $25.83 Target Price for Crispr Therapeutics AG (CRSP)Petro Global News 24 Crispr Therapeutics AG (CRSP) Coverage Initiated by Analysts at Chardan CapitalBBNS Chaffey Breeze –Sports Perspectives –Community Financial News all 8 news articles » |